CAMBRIDGE, England--(BUSINESS WIRE)--Biotica announces its consolidation of the polyketide engineering intellectual property (IP) space, via acquisition of IP from Bristol-Myers Squibb Company (NYSE:BMY). Combined with Biotica’s existing IP and proprietary know-how, this acquisition confirms Biotica’s leading position in polyketide therapeutics, a biologically rich and broadly applicable class of drugs.
